摘要
目的分析新诊断2型糖尿病患者在强化治疗后应用利拉鲁肽的疗效以及对长期临床缓解产生的影响。方法研究抽选2019年1—12月期间于该院就诊的60例新诊断为2型糖尿病的患者,以随机数字表法分别纳入对照组、研究组,各30例。所有患者经皮下胰岛素注射短期强化治疗后,对照组口服盐酸二甲双胍片,研究组则使用利拉鲁肽皮下注射,对治疗后的相关指标进行对比分析。结果治疗后,空腹血糖值:研究组(6.04±1.05)mmol/L低于对照组(7.09±1.37)mmol/L,糖化血红蛋白浓度:研究组(6.35±0.79)%低于对照组(7.06±0.99)%,餐后2 h血糖值:研究组(7.08±2.11)mmol/L低于对照组(10.83±3.66)mmol/L;β细胞功能指数:研究组(78.28±10.44)高于对照组(69.44±9.77),BMI指数:研究组(22.77±1.47)kg/m^2低于对照组(24.38±1.34)kg/m^2,两组数值差异有统计学意义(P<0.05)。结论在新诊断2型糖尿病的强化治疗后应用利拉鲁肽可以获得更高的临床缓解率与更有效的血糖控制效果,患者β细胞功能也得到改善。
Objective To analyze the efficacy and long-term clinical remission of newly diagnosed type 2 diabetes patients after intensive treatment.Methods From January to December 2019,60 newly diagnosed type 2 diabetes patients were selected and included in the control group and the study group with random number table method,30 cases each.After short-term intensive treatment with subcutaneous insulin injection in all patients,metformin hydrochloride tablets were taken orally in the control group,and lilaru peptide was used in the study group to compare and analyze the related indexes after treatment.Results After treatment,fasting blood glucose value:the study group’s(6.04±1.05)mmol/L was lower than the control group’s(7.09±1.37)mmol/L,glycosylated hemoglobin concentration:the study group’s(6.35±0.79)%was lower than the control group’s(7.06±0.99)%,2 h postprandial blood glucose level:the study group’s(7.08±2.11)mmol/L was lower than the control group’s(10.83±3.66)mmol/L;βcell function index:the study group’s(78.28±10.44)was higher than the control group’s(69.44±9.77),the BMI index:the study group’s(22.77±1.47)kg/m^2 was lower than the control group(24.38±1.34)kg/m^2,and the two groups were statistically significant differences(P<0.05).Conclusion After the intensive treatment of newly diagnosed type 2 diabetes mellitus,the application of lilaru peptide can obtain higher clinical remission rate and more effective blood glucose control effect.The patients’sβthe improvement of cell function was also improved.
作者
安美银
AN Mei-yin(Department of Pharmacy,Ulan Qab Central Hospital,Ulan Qab,Inner Mongolia Autonomous Region,012000 China)
出处
《糖尿病新世界》
2020年第21期83-85,共3页
Diabetes New World Magazine
关键词
2型糖尿病
强化治疗
利拉鲁肽
二甲双胍
Type 2 diabetes mellitus
Intensive therapy
Liraglutide
Metformin
